{"id":54270,"date":"2026-01-15T22:26:03","date_gmt":"2026-01-15T14:26:03","guid":{"rendered":"https:\/\/flcube.com\/?p=54270"},"modified":"2026-01-15T22:26:04","modified_gmt":"2026-01-15T14:26:04","slug":"abm-therapeutics-licenses-mek1-2-inhibitor-abm-168-to-mosaica-medicines-for-global-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54270","title":{"rendered":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development"},"content":{"rendered":"\n<p><strong>ABM Therapeutics Inc.<\/strong> announced a licensing agreement granting <strong>Mosaica Medicines<\/strong> global rights to <strong>ABM\u2011168<\/strong>, an in\u2011house developed <strong>allosteric MEK1\/2 inhibitor<\/strong> currently in <strong>Phase\u202fI clinical trials<\/strong> for advanced solid tumors with a focus on <strong>brain metastases and primary brain tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>ABM Therapeutics Inc. (Shanghai\u2011based)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Mosaica Medicines (US\u2011based)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>ABM\u2011168 (allosteric MEK1\/2 inhibitor)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed<\/td><\/tr><tr><td><strong>Milestones<\/strong><\/td><td>R&amp;D, regulatory, and marketing milestone payments<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global rights<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase\u202fI (US and China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Allosteric MEK1\/2 inhibitor<\/strong> that blocks the MAPK\/ERK signaling pathway, demonstrating <strong>antitumor activity<\/strong> in multiple preclinical studies<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Designed to <strong>penetrate the blood\u2011brain barrier<\/strong>, making it suitable for <strong>brain metastases and primary brain tumors<\/strong>\u2014an area with limited therapeutic options<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral small molecule with favorable pharmacokinetic profile<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Potential <strong>first\u2011in\u2011class<\/strong> MEK inhibitor for CNS\u2011active oncology indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-status\">Clinical Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Approval:<\/strong> <strong>FDA IND approval<\/strong> granted <strong>October\u202f2022<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202fI ongoing<\/strong> at multiple US oncology centers in patients with advanced solid tumors<\/li>\n\n\n\n<li><strong>China Approval:<\/strong> <strong>NMPA approval<\/strong> granted <strong>August\u202f2023<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202fI study<\/strong> in patients with advanced solid tumors, focusing on brain metastases and primary brain tumors<\/li>\n\n\n\n<li><strong>Next Milestone:<\/strong> <strong>Phase\u202fI data<\/strong> expected <strong>Q3\u202f2026<\/strong> to support dose\u2011expansion cohorts<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>US<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Brain Metastases (Annual Cases)<\/strong><\/td><td>200,000<\/td><td>450,000<\/td><td>1.2\u202fmillion<\/td><\/tr><tr><td><strong>Primary Brain Tumors<\/strong><\/td><td>25,000<\/td><td>80,000<\/td><td>300,000<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>$1.2\u202fbillion<\/td><td>$2.8\u202fbillion<\/td><td>$6.5\u202fbillion<\/td><\/tr><tr><td><strong>MEK Inhibitor Penetration<\/strong><\/td><td>&lt;5\u202f%<\/td><td>&lt;3\u202f%<\/td><td>&lt;4\u202f%<\/td><\/tr><tr><td><strong>CNS\u2011Active MEK Inhibitors<\/strong><\/td><td>None approved<\/td><td>None approved<\/td><td>None approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trametinib<\/strong> (Novartis) \u2013 Approved for melanoma, NSCLC; limited CNS penetration<\/li>\n\n\n\n<li><strong>Cobimetinib<\/strong> (Roche\/Exelixis) \u2013 Approved for melanoma; no CNS activity<\/li>\n\n\n\n<li><strong>Binimetinib<\/strong> (Pfizer) \u2013 Approved for melanoma; no CNS activity<\/li>\n\n\n\n<li><strong>ABM\u2011168<\/strong> \u2013 <strong>Only MEK inhibitor<\/strong> in development with <strong>CNS\u2011active design<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Value:<\/strong> Licensing deal validates ABM\u2011168\u2019s <strong>differentiated CNS\u2011active profile<\/strong> and provides <strong>non\u2011dilutive funding<\/strong> for Phase\u202fI\/II development<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Mosaica Medicines will lead <strong>global Phase\u202fII\/III development<\/strong> and regulatory submissions; ABM Therapeutics retains <strong>co\u2011development rights in China<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> ABM Therapeutics\u2019 <strong>Shanghai facility<\/strong> will supply clinical material for China trials; Mosaica will establish US\/EU supply chain<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> If approved, ABM\u2011168 could capture <strong>$300\u2011500\u202fmillion<\/strong> in peak annual sales from the <strong>CNS\u2011active MEK inhibitor niche<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for ABM\u2011168. Actual results may differ due to clinical trial outcomes, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,93],"tags":[2438,16,4554],"class_list":["post-54270","post","type-post","status-publish","format-standard","hentry","category-company","category-digital","tag-abm-therapeutics","tag-cancer","tag-mosaica-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54270\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development\" \/>\n<meta property=\"og:description\" content=\"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54270\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:26:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T14:26:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ABM Therapeutics Licenses MEK1\\\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development\",\"datePublished\":\"2026-01-15T14:26:03+00:00\",\"dateModified\":\"2026-01-15T14:26:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ABM Therapeutics\",\"Cancer\",\"Mosaica Medicines\"],\"articleSection\":[\"Company\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54270#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54270\",\"name\":\"ABM Therapeutics Licenses MEK1\\\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:26:03+00:00\",\"dateModified\":\"2026-01-15T14:26:04+00:00\",\"description\":\"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\\\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54270\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54270#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABM Therapeutics Licenses MEK1\\\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development - Insight, China&#039;s Pharmaceutical Industry","description":"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54270","og_locale":"en_US","og_type":"article","og_title":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development","og_description":"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.","og_url":"https:\/\/flcube.com\/?p=54270","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:26:03+00:00","article_modified_time":"2026-01-15T14:26:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54270#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54270"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development","datePublished":"2026-01-15T14:26:03+00:00","dateModified":"2026-01-15T14:26:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54270"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ABM Therapeutics","Cancer","Mosaica Medicines"],"articleSection":["Company","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54270#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54270","url":"https:\/\/flcube.com\/?p=54270","name":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:26:03+00:00","dateModified":"2026-01-15T14:26:04+00:00","description":"ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM\u2011168, an in\u2011house developed allosteric MEK1\/2 inhibitor currently in Phase\u202fI clinical trials for advanced solid tumors with a focus on brain metastases and primary brain tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54270#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54270"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54270#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ABM Therapeutics Licenses MEK1\/2 Inhibitor ABM\u2011168 to Mosaica Medicines for Global Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54270"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54270\/revisions"}],"predecessor-version":[{"id":54274,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54270\/revisions\/54274"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}